Chronic lymphocytic leukemia clinical staging: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(25 intermediate revisions by 5 users not shown)
Line 3: Line 3:
{{CMG}} {{AE}}{{HL}}
{{CMG}} {{AE}}{{HL}}
==Overview==
==Overview==
According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], [[hemoglobin]] level, [[platelet]]s level, presence of [[splenomegaly]], and presence of [[lymphadenopathy]].<ref name="pmid1139039">{{cite journal| author=Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS| title=Clinical staging of chronic lymphocytic leukemia. | journal=Blood | year= 1975 | volume= 46 | issue= 2 | pages= 219-34 | pmid=1139039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1139039  }} </ref> While according to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], the presence of [[anemia]] or [[thrombocytopenia]], and the involvement of three or more lymph node regions.<ref name="pmid7237385">{{cite journal| author=Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al.| title=A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. | journal=Cancer | year= 1981 | volume= 48 | issue= 1 | pages= 198-206 | pmid=7237385 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7237385  }} </ref> The stage of the tumor is one of the important factors which determine the optimal management protocol of chronic lymphocytic leukemia patients.<ref name="pmid25461996">Nabhan C, Rosen ST (2014) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=25461996 Chronic lymphocytic leukemia: a clinical review.] ''JAMA'' 312 (21):2265-76. [http://dx.doi.org/10.1001/jama.2014.14553 DOI:10.1001/jama.2014.14553] PMID: [http://pubmed.gov/25461996 25461996]</ref>
According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], [[hemoglobin]] level, [[platelet]] level, presence of [[splenomegaly]], and presence of [[lymphadenopathy]]. According to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], the presence of [[anemia]] or [[thrombocytopenia]], and the involvement of three or more lymphoid regions. The tumor stage is considered one of the important factors that determine the optimal management protocol of chronic lymphocytic leukemia patients.


==Staging System==
==Staging System==
===Rai Staging System===
===Rai Staging System:===
According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], [[hemoglobin]] level, [[platelet]]s level, presence of [[splenomegaly]], and presence of [[lymphadenopathy]].<ref name="pmid1139039">{{cite journal| author=Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS| title=Clinical staging of chronic lymphocytic leukemia. | journal=Blood | year= 1975 | volume= 46 | issue= 2 | pages= 219-34 | pmid=1139039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1139039  }} </ref>  
According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], [[hemoglobin]] level, [[platelet]]s level, presence of [[splenomegaly]], and presence of [[lymphadenopathy]].<ref name="pmid11390392">{{cite journal |vauthors=Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS |title=Clinical staging of chronic lymphocytic leukemia |journal=Blood |volume=46 |issue=2 |pages=219–34 |date=August 1975 |pmid=1139039 |doi= |url=}}</ref><ref name="pmid3357070">{{cite journal |vauthors=MacDougall BK, Weinerman BH |title=Staging and prognosis of chronic lymphocytic leukemia: the Manitoba experience |journal=J Gen Intern Med |volume=3 |issue=2 |pages=139–43 |date=1988 |pmid=3357070 |doi= |url=}}</ref><ref name="pmid9482526">{{cite journal |vauthors=Zwiebel JA, Cheson BD |title=Chronic lymphocytic leukemia: staging and prognostic factors |journal=Semin. Oncol. |volume=25 |issue=1 |pages=42–59 |date=February 1998 |pmid=9482526 |doi= |url=}}</ref><ref name="pmid28782884">{{cite journal |vauthors=Hallek M |title=Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment |journal=Am. J. Hematol. |volume=92 |issue=9 |pages=946–965 |date=September 2017 |pmid=28782884 |doi=10.1002/ajh.24826 |url=}}</ref>  


{| style="border: 0px; font-size: 90%; margin: 3px; width: 1050px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1050px"
|valign=top|
| valign="top" |
|+
|+
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Stage'''}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|'''Stage'''}}
Line 22: Line 22:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage 0'''
'''Stage 0'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>11 g/dL
>11 g/dL
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>100,000/L
>100,000/L
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent  
Absent  
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent
Absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>150 months
>150 months


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage 1'''
'''Stage 1'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>11 g/dL
>11 g/dL
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>100,000/L
>100,000/L
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent  
Absent  
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
101 months
101 months


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage 2'''
'''Stage 2'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>11 g/dL
>11 g/dL
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>100,000/L
>100,000/L
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or absent
Present or absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
71 months
71 months


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage 3'''
'''Stage 3'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
<11 g/dL
'''<11''' g/dL
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
>100,000/L
>100,000/L
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or absent
Present or absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or absent  
Present or absent  
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
19 months
19 months


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage 4'''
'''Stage 4'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
<11 g/dL or >11g/dL
<11 g/dL '''or''' >11g/dL
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
<100,000/L
'''<100,000'''/L
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
'''Present'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or absent
Present or absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or absent
Present or absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
19 months
19 months
|}
|}
The staging is further modified into 3 groups:<ref name="pmid18216293">{{cite journal |vauthors=Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ |title=Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines |journal=Blood |volume=111 |issue=12 |pages=5446–56 |date=June 2008 |pmid=18216293 |pmc=2972576 |doi=10.1182/blood-2007-06-093906 |url=}}</ref>
* '''Low Risk''': Stage 0
* '''Intermediate Risk''': Stages 1 and 2 combined
* '''High Risk''': Stage 3 and 4 combined


===Binet Staging System===
===Binet Staging System===
According to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], the presence of [[anemia]] or [[thrombocytopenia]], and the involvement of three or more lymph node regions.<ref name="pmid7237385">{{cite journal| author=Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J et al.| title=A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. | journal=Cancer | year= 1981 | volume= 48 | issue= 1 | pages= 198-206 | pmid=7237385 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7237385  }} </ref>
According to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of [[lymphocytosis]], the presence of [[anemia]] or [[thrombocytopenia]], and the involvement of three or more lymphoid regions: cervical, axillary and inguinal lymph nodes, and spleen and liver.<ref name="pmid7237385">{{cite journal |vauthors=Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F |title=A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis |journal=Cancer |volume=48 |issue=1 |pages=198–206 |date=July 1981 |pmid=7237385 |doi= |url=}}</ref><ref name="pmid33570702">{{cite journal |vauthors=MacDougall BK, Weinerman BH |title=Staging and prognosis of chronic lymphocytic leukemia: the Manitoba experience |journal=J Gen Intern Med |volume=3 |issue=2 |pages=139–43 |date=1988 |pmid=3357070 |doi= |url=}}</ref><ref name="pmid94825262">{{cite journal |vauthors=Zwiebel JA, Cheson BD |title=Chronic lymphocytic leukemia: staging and prognostic factors |journal=Semin. Oncol. |volume=25 |issue=1 |pages=42–59 |date=February 1998 |pmid=9482526 |doi= |url=}}</ref><ref name="pmid287828842">{{cite journal |vauthors=Hallek M |title=Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment |journal=Am. J. Hematol. |volume=92 |issue=9 |pages=946–965 |date=September 2017 |pmid=28782884 |doi=10.1002/ajh.24826 |url=}}</ref>


{| style="border: 0px; font-size: 90%; margin: 3px; width: 1050px"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1050px"
|valign=top|
| valign="top" |
|+
|+
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|'''Stage'''}}
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|'''Stage'''}}
Line 120: Line 125:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage A'''
'''Stage A'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
Present
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent
Absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent
2 or less lymphoid regions
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Almost normal age and sex adjusted survival rate
Almost normal age and sex adjusted survival rate
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage B'''
'''Stage B'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
Present
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Absent
Absent
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
>3 lymphoid regions
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
7 years
7 years


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
'''Stage C'''
'''Stage C'''
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
Present
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present
Present
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Present or Absent
>3 lymphoid regions
| style="padding: 5px 5px; background: #F5F5F5;" align=center|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
2 years
2 years
|}
|}
Line 171: Line 176:


{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 15:54, 28 February 2019

Chronic lymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic lymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic lymphocytic leukemia clinical staging On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic lymphocytic leukemia clinical staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic lymphocytic leukemia clinical staging

CDC on Chronic lymphocytic leukemia clinical staging

Chronic lymphocytic leukemia clinical staging in the news

Blogs on Chronic lymphocytic leukemia clinical staging

Directions to Hospitals Treating Chronic lymphocytic leukemia

Risk calculators and risk factors for Chronic lymphocytic leukemia clinical staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of lymphocytosis, hemoglobin level, platelet level, presence of splenomegaly, and presence of lymphadenopathy. According to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of lymphocytosis, the presence of anemia or thrombocytopenia, and the involvement of three or more lymphoid regions. The tumor stage is considered one of the important factors that determine the optimal management protocol of chronic lymphocytic leukemia patients.

Staging System

Rai Staging System:

According to the Rai Staging System, there are five stages of chronic lymphocytic leukemia based on the degree of lymphocytosis, hemoglobin level, platelets level, presence of splenomegaly, and presence of lymphadenopathy.[1][2][3][4]

Stage Hemoglobin Level Platelets Level Lymphocytosis Splenomegaly Lymphadenopathy Median Survival

Stage 0

>11 g/dL

>100,000/L

Present

Absent

Absent

>150 months

Stage 1

>11 g/dL

>100,000/L

Present

Absent

Present

101 months

Stage 2

>11 g/dL

>100,000/L

Present

Present

Present or absent

71 months

Stage 3

<11 g/dL

>100,000/L

Present

Present or absent

Present or absent

19 months

Stage 4

<11 g/dL or >11g/dL

<100,000/L

Present

Present or absent

Present or absent

19 months

The staging is further modified into 3 groups:[5]

  • Low Risk: Stage 0
  • Intermediate Risk: Stages 1 and 2 combined
  • High Risk: Stage 3 and 4 combined

Binet Staging System

According to the Binet Staging System, there are three stages of chronic lymphocytic leukemia based on the degree of lymphocytosis, the presence of anemia or thrombocytopenia, and the involvement of three or more lymphoid regions: cervical, axillary and inguinal lymph nodes, and spleen and liver.[6][7][8][9]

Stage Lymphocytosis Anemia or Thrombocytopenia Lymphadenopathy Median Survival

Stage A

Present

Absent

2 or less lymphoid regions

Almost normal age and sex adjusted survival rate

Stage B

Present

Absent

>3 lymphoid regions

7 years

Stage C

Present

Present

>3 lymphoid regions

2 years

References

  1. ↑ Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (August 1975). "Clinical staging of chronic lymphocytic leukemia". Blood. 46 (2): 219–34. PMID 1139039.
  2. ↑ MacDougall BK, Weinerman BH (1988). "Staging and prognosis of chronic lymphocytic leukemia: the Manitoba experience". J Gen Intern Med. 3 (2): 139–43. PMID 3357070.
  3. ↑ Zwiebel JA, Cheson BD (February 1998). "Chronic lymphocytic leukemia: staging and prognostic factors". Semin. Oncol. 25 (1): 42–59. PMID 9482526.
  4. ↑ Hallek M (September 2017). "Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment". Am. J. Hematol. 92 (9): 946–965. doi:10.1002/ajh.24826. PMID 28782884.
  5. ↑ Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (June 2008). "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines". Blood. 111 (12): 5446–56. doi:10.1182/blood-2007-06-093906. PMC 2972576. PMID 18216293.
  6. ↑ Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (July 1981). "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis". Cancer. 48 (1): 198–206. PMID 7237385.
  7. ↑ MacDougall BK, Weinerman BH (1988). "Staging and prognosis of chronic lymphocytic leukemia: the Manitoba experience". J Gen Intern Med. 3 (2): 139–43. PMID 3357070.
  8. ↑ Zwiebel JA, Cheson BD (February 1998). "Chronic lymphocytic leukemia: staging and prognostic factors". Semin. Oncol. 25 (1): 42–59. PMID 9482526.
  9. ↑ Hallek M (September 2017). "Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment". Am. J. Hematol. 92 (9): 946–965. doi:10.1002/ajh.24826. PMID 28782884.

Template:Hematology


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_lymphocytic_leukemia_clinical_staging&oldid=1555049"